Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.46 |
| ▸ | POLA1 | P09884 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696378 | 0.87 | EGLN1 (0.47) | EGLN1CYP1A1HPGDLMNANR3C1 | |
| SCHEMBL6691160 | 0.85 | LMNA (0.47) | EGLN1CYP1A1HPGDLMNANR3C1 | |
| SCHEMBL6695156 | 0.84 | ADORA2A (0.57) | EGLN1CYP1A1HPGDLMNANR3C1 | |
| SCHEMBL6699580 | 0.82 | EGLN1 (0.43) | EGLN1CYP1A1HPGDLMNANR3C1 | |
| SCHEMBL6699267 | 0.79 | MAPK1 (0.42) | EGLN1CYP1A1HPGDLMNANR3C1 | |
| SCHEMBL6692811 | 0.79 | KCNH2 (0.51) | POLA1KMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL6202038 | 0.78 | EGLN1 (0.54) | EGLN1HPGDLMNANR3C1POLA1 | |
| SCHEMBL15336604 | 0.77 | POLA1 (0.47) | EGLN1CYP1A1HPGDLMNANR3C1 | |
| SCHEMBL6200288 | 0.77 | AKR1B1 (0.48) | EGLN1HPGDLMNANR3C1POLA1 | |
| SCHEMBL6198601 | 0.77 | EGLN1 (0.50) | EGLN1CYP1A1HPGDLMNANR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | claimed |
| EP-1265896-A1 | 4-HYDROXY-1,8-NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| US-6413958-B2 | FOR TREATMENT/PREVENTION OF INFECTION OF HERPES SIMPLEX VIRUS, VARICELLA ZOSTER VIRUS, HUMAN CYTOMEGALOVIRUS, OR EPSTEIN-BARR VIRUS; ENZYME INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2002-07-02 | — | — | US | claimed |
| US-20020007066-A1 | 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-01-17 | — | — | US | claimed |
| WO-2001070742-A1 | 4-HYDROXY-1,8-NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-09-27 | — | — | WO | claimed |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | disclosed |
| US-6693114-B2 | N-(4-CHLOROBENZYL)-6-(3-HYDROXY-1-PROPYNYL)-1-7-DIMETHYL-4-OXO-1,4 -DIHYDRO(1,8) NAPHTHYRIDINE-3-CARBOXAMIDE FOR EXAMPLE; INHIBITING VIRAL DNA POLYMERASE; TREATING HERPES VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY | 2004-02-17 | — | — | US | disclosed |
| EP-1265896-A1 | 4-HYDROXY-1,8-NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1265895-A1 | 4-OXO-1,4-DIHYDRO 1,8]NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020177604-A1 | 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents | VAILLANCOURT VALERIE A (US) | 2002-11-28 | — | — | US | disclosed |
| US-6451811-B2 | HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2002-09-17 | — | — | US | disclosed |
| US-6413958-B2 | FOR TREATMENT/PREVENTION OF INFECTION OF HERPES SIMPLEX VIRUS, VARICELLA ZOSTER VIRUS, HUMAN CYTOMEGALOVIRUS, OR EPSTEIN-BARR VIRUS; ENZYME INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2002-07-02 | — | — | US | disclosed |
| US-20020019413-A1 | 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-14 | — | — | US | disclosed |
| US-20020007066-A1 | 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-01-17 | — | — | US | disclosed |
| WO-2001074816-A1 | 4-OXO-1,4-DIHYDRO[1,8]NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001070742-A1 | 4-HYDROXY-1,8-NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019413-A1 | 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents | IRF3, ZC3HAV1, EIF2AK2 | EGLN1 1009/4885CYP1A1 1780/4885HPGD 2127/4885 |
| US-20020177604-A1 | 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents | IRF3, ZC3HAV1, EIF2AK2 | EGLN1 1009/4885CYP1A1 1780/4885HPGD 2127/4885 |
| US-20020007066-A1 | 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents | CNR1, HAVCR2, NR1H4 | EGLN1 569/4885CYP1A1 936/4885HPGD 1309/4885 |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, MSR1, NR1H2 | EGLN1 1633/4885CYP1A1 2804/4885HPGD 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.